13F Holdings
中文EN

TCRX TScan Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1783328 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-38.4%
TTM net income YoY19.3%
TTM EPS YoY20.5%
Revenue 3-yr CAGR-32.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2,246.8%
Net margin-2,219.2%
FCF margin-2,153.3%
EBITDA margin-2,192.3%

Returns

ROE-126.4%
ROA-57.0%
ROIC (approx.)-3,777.3%
Asset turnover0.03x

Leverage & solvency

Liabilities / assets73.1%
Debt / equity0.87x
Current ratio2.03x
Interest coverage-40.67x

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue14.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$10.32M$2.82M$21.05M$13.54M$10.14M
R&D expense$114.15M$107.35M$88.15M$59.82M$44.95M
SG&A expense$31.99M$30.29M$26.35M$20.35M$13.83M
Operating income-$135.81M-$134.82M-$93.46M-$66.64M-$48.64M
Interest expense$2.77M$3.65M$3.76M$1.18M—
Income tax$0————
Net income-$129.77M-$127.50M-$89.22M-$66.22M-$48.62M
EBITDA-$132.91M-$130.72M-$88.06M-$61.54M-$45.34M
EPS (basic)-1.00-1.14-1.36-2.75-4.17
EPS (diluted)-1.00-1.14-1.36-2.75-4.17
Weighted avg. shares (diluted)129.78M111.99M65.60M24.05M11.66M
Balance sheet
Cash & equivalents$152.41M$183.72M$138.39M$125.06M$166.44M
Short-term investments—$111.42M$58.69M——
Current assets$157.21M$292.72M$194.24M$124.13M$165.65M
PP&E, net$8.71M$7.24M$7.74M$10.10M$11.77M
Total assets$228.79M$371.12M$272.15M$199.09M$188.11M
Current liabilities$18.70M$35.96M$29.82M$17.30M$21.34M
Short-term debt——$3.35M——
Long-term debt$32.53M$32.07M$26.70M$29.29M—
Total debt$32.53M$32.07M$30.05M$29.29M—
Total liabilities$105.67M$130.15M$121.28M$99.66M$27.33M
Shareholders' equity$123.12M$240.97M$150.87M$99.43M$160.78M
Net debt-$119.87M-$151.65M-$108.34M-$95.77M—
Cash flow statement
Operating cash flow-$135.32M-$110.82M-$61.36M-$66.50M-$48.68M
Capital expenditure$4.41M$3.83M$3.15M$4.22M$9.94M
Free cash flow-$139.73M-$114.65M-$64.50M-$70.73M-$58.62M
Investing cash flow$109.37M-$52.61M-$60.76M-$4.22M-$9.94M
Financing cash flow-$336,000$208.76M$135.44M$29.36M$189.67M
Depreciation & amortization$2.90M$4.10M$5.40M$5.10M$3.30M
Stock-based compensation$11.71M$9.55M$5.21M$4.55M$2.52M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.